Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617959 | 0.95 | ALDH1A1 (0.50) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL1618842 | 0.90 | ALDH1A1 (0.42) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL1619167 | 0.87 | TP53 (0.43) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL1619270 | 0.86 | ALDH1A1 (0.47) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL2643221 | 0.86 | MAPT (0.50) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL2643810 | 0.85 | MAPT (0.49) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL2666550 | 0.83 | PORCN (0.37) | HCAR3PRKAA2 | |
| SCHEMBL2643716 | 0.78 | ALDH1A1 (0.52) | MAPTALDH1A1GAAHTTNPSR1 | |
| SCHEMBL2643171 | 0.78 | MAPT (0.41) | MAPTALDH1A1POLBKDM4EPRKAA2 | |
| SCHEMBL2664888 | 0.78 | MAPT (0.47) | MAPTALDH1A1GAAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | MAPT 3048/4885ALDH1A1 1644/4885GAA 221/4885 |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | GCK, GCKR, GPR119 | MAPT 3131/4885ALDH1A1 1711/4885GAA 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.